Biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The powerful physiological effects of antibodies, hormones, enzymes and other biological drugs also increase the need for safety and adherence. Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies. New injectable delivery device designs currently being developed will create new opportunities for alternative injection methods. Partnerships between device suppliers and pharmaceutical companies will foster market acceptance of new injection devices for a host of new therapies such as therapeutic vaccines, DNA-based drugs, and protein-derived biologics.
Injection Devices for Biologicals Report Brochure (Download PDF)
Injection Devices for Biologicals Report Order Form (Download PDF)
Injection Devices for Biological Drugs – What You Will Learn
- What are the product and user requirements that drive the biological drug-device selection process?
- What are the essential design factors, technologies and market development issues for injection devices capable of administering biological dugs?
- What is the impact of development-stage biological manufacturing process changes on device go-to-market readiness and how has it changed in recent years?
- How do device selection decisions align across biological drug classes? Therapeutic targets? Market segments?
- What is the impact of drug-device dependencies on pre- and post-marketing product life cycle management?
- What are the significant economic, technology, and regulatory factors affecting the market for biological drug injection devices?
Injection Devices for Biological Drugs – Summary of Contents
The Market Opportunity
Unmet Patient Needs
Device Material Selection Factors
The Biological Drug Global Supply Chain
Biological Drug Delivery – Challenges and Limitations
Pre- and Post-Manufacturing Engineering
Lyophilization and Reconstitution
Viscosities and Volumes
Drug Strategies & Therapeutic Protein Packaging
Device Market Share
Device Supplier Segment Activity
Emerging Injection Devices for Biological Drugs
Injectable Biologicals – Product Analysis by Drug Class
Insulins & GLP Analogs
Therapeutic Market Segment Analysis
Patient Preferences and Self-Administration
Pre- and Post-marketing Device Evolution